[go: up one dir, main page]

WO2011004972A3 - Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 - Google Patents

Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 Download PDF

Info

Publication number
WO2011004972A3
WO2011004972A3 PCT/KR2010/003790 KR2010003790W WO2011004972A3 WO 2011004972 A3 WO2011004972 A3 WO 2011004972A3 KR 2010003790 W KR2010003790 W KR 2010003790W WO 2011004972 A3 WO2011004972 A3 WO 2011004972A3
Authority
WO
WIPO (PCT)
Prior art keywords
piperazinyl
ccr2
ccr2 antagonist
aminopyrrolidine derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/003790
Other languages
English (en)
French (fr)
Other versions
WO2011004972A2 (ko
Inventor
임지웅
김종훈
옥민호
나용호
오유나
강소희
이정옥
손정덕
이승우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Ji Chemical Co Ltd
Original Assignee
Yang Ji Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Ji Chemical Co Ltd filed Critical Yang Ji Chemical Co Ltd
Priority to BR112012000609A priority Critical patent/BR112012000609A2/pt
Priority to CA2767734A priority patent/CA2767734A1/en
Priority to US13/383,104 priority patent/US8575173B2/en
Priority to EP10797246.5A priority patent/EP2452939B1/en
Priority to JP2012519459A priority patent/JP5474189B2/ja
Priority to RU2012104633/04A priority patent/RU2012104633A/ru
Priority to CN201080031168.9A priority patent/CN102498109B/zh
Publication of WO2011004972A2 publication Critical patent/WO2011004972A2/ko
Publication of WO2011004972A3 publication Critical patent/WO2011004972A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

본 발명은 CCR2 (chemokine receptor 2) 길항 효과를 나타내는 화학식 1의 화합물, 이것의 염 또는 이성질체에 관한 것으로서, 이러한 화합물은 류마티스 관절염, 동맥경화증, 다발성경화증, 천식 및 기타 CCR2에 관련된 여러 질환을 치료, 예방 또는 개선하는 데 유용하다. 화학식 1에서 R1, R2, R3, R4, R5, R6, R7, R8 및 R9는 본 명세서에서 정의된 바와 같다.
PCT/KR2010/003790 2009-07-10 2010-06-11 Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 Ceased WO2011004972A2 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR112012000609A BR112012000609A2 (pt) 2009-07-10 2010-06-11 piperaziniletil 3-aminopirrolidine derivados como antagonistas ccr2
CA2767734A CA2767734A1 (en) 2009-07-10 2010-06-11 Piperazinyl 3-aminopyrrolidine derivatives as a ccr2 antagonist
US13/383,104 US8575173B2 (en) 2009-07-10 2010-06-11 Piperazinyl 3-aminopyrrolidine derivatives as a CCR2 antagonists
EP10797246.5A EP2452939B1 (en) 2009-07-10 2010-06-11 Piperazinyl 3-aminopyrrolidine derivatives as a ccr2 antagonist
JP2012519459A JP5474189B2 (ja) 2009-07-10 2010-06-11 Ｃｃｒ２拮抗剤としてのピペラジニルエチル３−アミノピロリジン誘導体ｐｉｐｅｒａｚｉｎｙｌ３−ａｍｉｎｏｐｙｒｒｏｌｉｄｉｎｅｄｅｒｉｖａｔｉｖｅｓａｓａｃｃｒ２ａｎｔａｇｏｎｉｓｔ｝
RU2012104633/04A RU2012104633A (ru) 2009-07-10 2010-06-11 Производные пиперазинил-3-аминопирролидина в качестве антагониста ccr2
CN201080031168.9A CN102498109B (zh) 2009-07-10 2010-06-11 作为ccr2拮抗剂的哌嗪基乙基3-氨基吡咯烷衍生物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0063136 2009-07-10
KR1020090063136A KR101151415B1 (ko) 2009-07-10 2009-07-10 Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체

Publications (2)

Publication Number Publication Date
WO2011004972A2 WO2011004972A2 (ko) 2011-01-13
WO2011004972A3 true WO2011004972A3 (ko) 2011-05-19

Family

ID=43429638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003790 Ceased WO2011004972A2 (ko) 2009-07-10 2010-06-11 Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체

Country Status (9)

Country Link
US (1) US8575173B2 (ko)
EP (1) EP2452939B1 (ko)
JP (1) JP5474189B2 (ko)
KR (1) KR101151415B1 (ko)
CN (1) CN102498109B (ko)
BR (1) BR112012000609A2 (ko)
CA (1) CA2767734A1 (ko)
RU (1) RU2012104633A (ko)
WO (1) WO2011004972A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101318656B1 (ko) * 2010-10-08 2013-10-16 양지화학 주식회사 항천식 활성을 가진 3-아미노피롤리딘 유도체를 포함하는 약학 조성물
KR101437067B1 (ko) * 2012-09-19 2014-09-05 이화여자대학교 산학협력단 항-ｃｘｃｌ2 또는 항-ｃｘｃｒ2 단일클론 항체를 포함하는 이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
CN105902546B (zh) * 2014-05-26 2019-01-18 中国医学科学院医药生物技术研究所 取代的哌嗪-1,4-二酰胺类化合物在制备治疗和/或预防炎症反应的药中的应用
MX382659B (es) 2014-05-28 2025-03-11 Bayer Cropscience Ag Proceso para la preparación de derivados de tiazol.
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075853A2 (en) * 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418951C (zh) 1997-11-18 2008-09-17 帝人医药株式会社 环胺衍生物及其作为药物的用途
ES2250132T3 (es) * 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
BRPI0316732B8 (pt) 2002-11-27 2021-05-25 Incyte Corp composto derivado de 3-aminopirrolidina e sua composição farmacêutica
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
JP4740151B2 (ja) * 2003-12-18 2011-08-03 インサイト コーポレイション ケモカイン受容体のモジュレーターとしての３‐シクロアルキルアミノピロリジン誘導体
KR20070063562A (ko) 2004-09-28 2007-06-19 얀센 파마슈티카 엔.브이. 치환 디피페리딘 ｃｃｒ２ 길항제
UY29219A1 (es) * 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
US20100016289A1 (en) 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007106797A2 (en) 2006-03-14 2007-09-20 Janssen Pharmaceutica, Nv A method of use for substituted dipiperidine ccr2 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075853A2 (en) * 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2452939A4 *

Also Published As

Publication number Publication date
CN102498109B (zh) 2014-04-16
EP2452939A4 (en) 2012-12-26
CA2767734A1 (en) 2011-01-13
CN102498109A (zh) 2012-06-13
RU2012104633A (ru) 2013-11-20
EP2452939A2 (en) 2012-05-16
BR112012000609A2 (pt) 2015-10-06
JP2012532865A (ja) 2012-12-20
KR101151415B1 (ko) 2012-06-01
EP2452939B1 (en) 2014-03-26
US8575173B2 (en) 2013-11-05
JP5474189B2 (ja) 2014-04-16
US20120190689A1 (en) 2012-07-26
WO2011004972A2 (ko) 2011-01-13
KR20110005532A (ko) 2011-01-18

Similar Documents

Publication Publication Date Title
WO2009065919A3 (de) Organische verbindungen
WO2009065920A3 (de) Verbindungen
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2010115736A3 (en) Dihydroorotate dehydrogenase inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2008020405A3 (en) Azetidine compounds as orexin receptor antagonists
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2009065922A3 (de) Organische verbindungen
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2010062038A2 (ko) 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2011004972A3 (ko) Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
WO2009055629A3 (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080031168.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797246

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13383104

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012519459

Country of ref document: JP

Ref document number: 2767734

Country of ref document: CA

Ref document number: 1201000081

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2010797246

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 957/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012104633

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012000609

Country of ref document: BR

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112012000609

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120110